CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
Eszopiclone +1 moredrug
Likely dose
Eszopiclone 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00645944
NCT00645944N/ACompleted
CompareCT.gov

Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

Yale University·interventional·Posted Mar 28, 2008·Updated Jul 16, 2015

In Brief

A clinical study evaluating Eszopiclone and Placebo for Insomnia and 3 related conditions. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life. In addition, we hypothesize that the insomnia treatment may also lead to observed improvements in other symptoms associated with schizophrenia such as cognitive impairments, obesity, and negative symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
CountriesUnited States
CollaboratorsSumitomo Pharma America, Inc.

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 28, 2008
Enrollment StartApr 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.3 years ago

Interventions

Eszopiclonedrug

Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.

Placebodrug

Placebo or inactive substance ("sugar pill")taken each night for all weeks of the study